Pacific Biosciences of California, Inc. (PACB)
NASDAQ: PACB · Real-Time Price · USD
1.400
-0.080 (-5.41%)
Jul 31, 2026, 4:00 PM EDT - Market closed
PACB Stock Forecast
Stock Price Forecast
According to 7 analysts polled by S&P Global, PACB stock has a consensus rating of "Buy" and an average price target of $2.46. The average 1-year stock price forecast is 75.71% higher than the current stock price, while the lowest is $1.50 (+7.14%) and the highest is $3.00 (+114.29%).
Price Target: $2.46 (+75.71%)
Analyst Consensus: Buy
Price Target
Chart* Price targets were last updated on May 11, 2026.
Analyst Ratings
The average analyst rating for PACB stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 5 | 3 | 3 | 3 | 2 | 2 |
| Sell | 0 | 1 | 1 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 8 | 8 | 8 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Barclays | Barclays | Sell Reiterates $1 → $1.5 | Sell | Reiterates | $1 → $1.5 | +7.14% | May 11, 2026 |
| TD Cowen | TD Cowen | Buy Reiterates $3 | Buy | Reiterates | $3 | +114.29% | May 8, 2026 |
| Piper Sandler | Piper Sandler | Hold Reiterates $2 | Hold | Reiterates | $2 | +42.86% | May 8, 2026 |
| Canaccord Genuity | Canaccord Genuity | Buy Reiterates $3 | Buy | Reiterates | $3 | +114.29% | May 8, 2026 |
| Guggenheim | Guggenheim | Hold Maintains n/a | Hold | Maintains | n/a | n/a | Feb 12, 2026 |
Financial Forecast
Revenue This Year
167.43M
from 160.01M
Increased by 4.64%
Revenue Next Year
194.28M
from 167.43M
Increased by 16.04%
EPS This Year
-0.51
from -0.53
EPS Next Year
-0.39
from -0.51
EPS and Forward PE are based on non-GAAP adjusted numbers.